DNA vaccines for targeting bacterial infections

References

• Stewart AJ, Devlin PM. The history of the smallpox vaccine. J. Infect.52(5), 329–334 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrera F, La Cava A, Rizzi M, Hahn BH, Indiveri F, Filaci G. Gene vaccination for the induction of immune tolerance. Ann. NY Acad. Sci.1110, 99–111 (2007).
   PubMed Web of Science ®Google Scholar
• Romano M, Huygen K. DNA vaccines against mycobacterial diseases. Expert Rev. Vaccines8(9), 1237–1250 (2009).
   PubMed Web of Science ®Google Scholar
• Davidson AH, Traub-Dargatz JL, Rodeheaver RM et al. Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J. Am. Vet. Med. Assoc.226(2), 240–245 (2005).
   PubMed Web of Science ®Google Scholar
• Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis. Aquat. Organ.64(1), 13–22 (2005).
   PubMed Web of Science ®Google Scholar
• Bergman PJ, Camps-Palau MA, McKnight JA et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine24(21), 4582–4585 (2006).
   PubMed Web of Science ®Google Scholar
• Thacker EL, Holtkamp DJ, Khan AS, Brown PA, Draghia-Akli R. Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J. Anim. Sci.84(3), 733–742 (2006).
   PubMed Web of Science ®Google Scholar
• Redding L, Weiner DB. DNA vaccines in veterinary use. Expert Rev. Vaccines8(9), 1251–1276 (2009).
   PubMed Web of Science ®Google Scholar
• Ito Y. A tumor-producing factor extracted by phenol from papillomatous tissue (Shope) of cottontail rabbits. Virology12, 596–601 (1960).
   PubMed Web of Science ®Google Scholar
• Atanasiu P, Orth G, Dragonas P. [Delayed specific antitumoral resistance in the hamster immunized shortly after birth with the polyoma virus.]. CR Hebd Seances Acad. Sci.254, 2250–2252 (1962).
   PubMedGoogle Scholar
• Kitsis RN, Buttrick PM, McNally EM, Kaplan ML, Leinwand LA. Hormonal modulation of a gene injected into rat heart in vivo.Proc. Natl Acad. Sci. USA88(10), 4138–4142 (1991).
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo.Science247(4949 Pt 1), 1465–1468 (1990).
   PubMed Web of Science ®Google Scholar
• Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation82(6), 2217–2221 (1990).
   PubMed Web of Science ®Google Scholar
• Tang D-C, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature356(6365), 152–154 (1992).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science259(5102), 1745–1749 (1993).
   PubMed Web of Science ®Google Scholar
• Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl Acad. Sci. USA90(24), 11478–11482 (1993).
   PubMed Web of Science ®Google Scholar
• Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA90(9), 4156–4160 (1993).
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology199(1), 132–140 (1994).
   PubMed Web of Science ®Google Scholar
• Cox GJ, Zamb TJ, Babiuk LA. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J. Virol.67(9), 5664–5667 (1993).
   PubMed Web of Science ®Google Scholar
• Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet.2(11), 1847–1851 (1993).
   PubMed Web of Science ®Google Scholar
• Kowalczyk DW, Ertl HC. Immune responses to DNA vaccines. Cell. Mol. Life Sci.55(5), 751–770 (1999).
   PubMed Web of Science ®Google Scholar
• Ritter T, Brandt C, Prosch S et al. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine12(8), 1163–1170 (2000).
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, He Z, Wang Y, Ertl HC. The effect of interferon-γ on genetic immunization. Vaccine15(8), 896–898 (1997).
   PubMed Web of Science ®Google Scholar
• Vanniasinkam T, Reddy ST, Ertl HC. DNA immunization using a non-viral promoter. Virology344(2), 412–420 (2006).
   PubMed Web of Science ®Google Scholar
• Shepherd CT, Scott MP. Construction and evaluation of a maize chimeric promoter with activity in kernel endosperm and embryo. Biotechnol. Appl. Biochem.52, 233–243 (2009).
   PubMed Web of Science ®Google Scholar
• Seleem MN, Jain N, Alqublan H, Vemulapalli R, Boyle SM, Sriranganathan N. Activity of native vs. synthetic promoters in Brucella.FEMS Microbiol. Lett.288(2), 211–215 (2008).
   PubMed Web of Science ®Google Scholar
• Tang CK, Pietersz GA. Intracellular detection and immune signaling pathways of DNA vaccines. Expert Rev. Vaccines8(9), 1161–1170 (2009).
   PubMed Web of Science ®Google Scholar
• Capone S, Zampaglione I, Vitelli A et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J. Immunol.177(10), 7462–7471 (2006).
   PubMed Web of Science ®Google Scholar
• Lutz CS. Alternative polyadenylation: a twist on mRNA 3´ end formation. ACS Chem. Biol.3(10), 609–617 (2008).
   PubMed Web of Science ®Google Scholar
• Xu ZL, Mizuguchi H, Ishii-Watabe A, Uchida E, Mayumi T, Hayakawa T. Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector. J. Control. Release81(1–2), 155–163 (2002).
   PubMed Web of Science ®Google Scholar
• Ada G. Overview of vaccines and vaccination. Mol. Biotechnol.29(3), 255–272 (2005).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Weiner DB. Development of more efficient and effective DNA vaccines. Expert Rev. Vaccines8(9), 1133–1134 (2009).
   PubMed Web of Science ®Google Scholar
• Tonheim TC, Bogwald J, Dalmo RA. What happens to the DNA vaccine in fish? A review of current knowledge. Fish Shellfish Immunol.25(1–2), 1–18 (2008).
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat. Rev. Genet.9(10), 776–788 (2008).
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Ertl HC. DNA vaccines. Curr. Mol. Med.1(2), 217–243 (2001).
   PubMedGoogle Scholar
• Nathanson N, Langmuir AD. The Cutter Incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. ii. Relationship of poliomyelitis to cutter vaccine. Am. J. Hyg.78, 29–60 (1963).
   PubMed Web of Science ®Google Scholar
• Bellet JS, Prose NS. Skin complications of Bacillus Calmette-Guerin immunization. Curr. Opin. Infect. Dis.18(2), 97–100 (2005).
   PubMedGoogle Scholar
• Cattamanchi A, Posavad CM, Wald A et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin. Vaccine Immunol.15(11), 1638–1643 (2008).
   PubMed Web of Science ®Google Scholar
• Delavallee L, Assier E, Denys A et al. Vaccination with cytokines in autoimmune diseases. Ann. Med.40(5), 343–351 (2008).
   PubMed Web of Science ®Google Scholar
• Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum. Vaccin.4(6), 453–456 (2008).
   PubMed Web of Science ®Google Scholar
• Tokuoka M, Tanaka M, Ono K, Takagi S, Shintani T, Gomi K. Codon optimization increases steady-state mRNA levels in Aspergillus oryzae heterologous gene expression. Appl. Environ. Microbiol.74(21), 6538–6546 (2008).
   PubMed Web of Science ®Google Scholar
• Li KB, Zhang XG, Ma J et al. Codon optimization of the H5N1 influenza virus HA gene gets high expression in mammalian cells. Bing Du Xue Bao24(2), 101–105 (2008).
   PubMedGoogle Scholar
• Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology116(2), 255–266 (2005).
   PubMed Web of Science ®Google Scholar
• Muthumani K, Lankaraman KM, Laddy DJ et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine26(40), 5128–5134 (2008).
   PubMed Web of Science ®Google Scholar
• Besse F, Ephrussi A. Translational control of localized mRNAs: restricting protein synthesis in space and time. Nat. Rev. Mol. Cell. Biol.9(12), 971–980 (2008).
   PubMed Web of Science ®Google Scholar
• Graf M, Deml L, Wagner R. Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Methods Mol. Med.94, 197–210 (2004).
   PubMedGoogle Scholar
• Kalwy S, Rance J, Young R. Toward more efficient protein expression: keep the message simple. Mol. Biotechnol.34(2), 151–156 (2006).
   PubMed Web of Science ®Google Scholar
• Olafsdottir G, Svansson V, Ingvarsson S, Marti E, Torsteinsdottir S. In vitro analysis of expression vectors for DNA vaccination of horses: the effect of a Kozak sequence. Acta Vet. Scand.50, 44 (2008).
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev.60(7), 795–804 (2008).
   PubMed Web of Science ®Google Scholar
• Li JM, Zhu DY. Therapeutic DNA vaccines against tuberculosis: a promising but arduous task. Chin. Med. J. (Engl.)119(13), 1103–1107 (2006).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv. Drug Deliv. Rev.61(3), 248–255 (2009).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Klaschik S, Tomaru K, Shirota H, Tross D, Ikeuchi H. Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants. Vaccine28(8), 1919–1923 (2010).
   PubMed Web of Science ®Google Scholar
• Angel JB, Cooper CL, Clinch J et al. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J. Immune Based Ther. Vaccines6, 4 (2008).
   PubMedGoogle Scholar
• Kindrachuk J, Potter J, Wilson HL, Griebel P, Babiuk LA, Napper S. Activation and regulation of Toll-like receptor 9: CpGs and beyond. Mini Rev. Med. Chem.8(6), 590–600 (2008).
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol.68(6), 793–806 (2000).
   PubMed Web of Science ®Google Scholar
• Verstrepen BE, Bins AD, Rollier CS et al. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine26(26), 3346–3351 (2008).
   PubMed Web of Science ®Google Scholar
• Lori F, Calarota SA, Lisziewicz J. Nanochemistry-based immunotherapy for HIV-1. Curr. Med. Chem.14(18), 1911–1919 (2007).
   PubMed Web of Science ®Google Scholar
• Watabe S, Xin K-Q, Ihata A et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine19(31), 4434–4444 (2001).
   PubMed Web of Science ®Google Scholar
• Xu J, Ding Y, Yang Y. Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome. Viral Immunol.21(4), 483–489 (2008).
   PubMed Web of Science ®Google Scholar
• Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods40(1), 86–97 (2006).
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Takashima Y, Hirayama S, Okada H. Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine. Int. J. Pharm.360(1–2), 164–170 (2008).
   PubMed Web of Science ®Google Scholar
• Brave A, Hallengard D, Schroder U, Blomberg P, Wahren B, Hinkula J. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses. Vaccine26(40), 5075–5078 (2008).
   PubMed Web of Science ®Google Scholar
• Guimaraes V, Innocentin S, Chatel JM et al. A new plasmid vector for DNA delivery using lactococci. Genet. Vaccines Ther.7(1), 4 (2009).
   PubMedGoogle Scholar
• Zaharoff DA, Barr RC, Li CY, Yuan F. Electromobility of plasmid DNA in tumor tissues during electric field-mediated gene delivery. Gene Ther.9(19), 1286–1290 (2002).
   PubMed Web of Science ®Google Scholar
• Chiarella P, Massi E, De Robertis M et al. Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration. Expert Opin. Biol. Ther.8(11), 1645–1657 (2008).
   PubMed Web of Science ®Google Scholar
• Escoffre JM, Portet T, Wasungu L, Teissie J, Dean D, Rols MP. What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol. Biotechnol.41(3), 286–295 (2009).
   PubMed Web of Science ®Google Scholar
• Rabussay D. Applicator and electrode design for in vivo DNA delivery by electroporation. Methods Mol. Biol.423, 35–59 (2008).
   PubMedGoogle Scholar
• Draghia-Akli R, Khan AS, Brown PA et al. Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine26(40), 5230–5237 (2008).
   PubMed Web of Science ®Google Scholar
• Hu H, Huang X, Tao L, Huang Y, Cui BA, Wang H. Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model. Vaccine27(11), 1758–1763 (2009).
   PubMed Web of Science ®Google Scholar
• Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine26(49), 6225–6231 (2008).
   PubMed Web of Science ®Google Scholar
• Rosati M, Valentin A, Jalah R et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine26(40), 5223–5229 (2008).
   PubMed Web of Science ®Google Scholar
• Hirao LA, Wu L, Khan AS et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine26(25), 3112–3120 (2008).
   PubMed Web of Science ®Google Scholar
• Foldvari M, Babiuk S, Badea I. DNA delivery for vaccination and therapeutics through the skin. Curr. Drug Deliv.3(1), 17–28 (2006).
   PubMedGoogle Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol.26(11), 1261–1268 (2008).
   PubMed Web of Science ®Google Scholar
• Vandermeulen G, Staes E, Vanderhaeghen ML, Bureau MF, Scherman D, Preat V. Optimisation of intradermal DNA electrotransfer for immunisation. J. Control Release124(1–2), 81–87 (2007).
   PubMed Web of Science ®Google Scholar
• Ogura M, Paliwal S, Mitragotri S. Low-frequency sonophoresis: current status and future prospects. Adv. Drug Deliv. Rev.60(10), 1218–1223 (2008).
   PubMed Web of Science ®Google Scholar
• Whitehead K, Mitragotri S. Mechanistic analysis of chemical permeation enhancers for oral drug delivery. Pharm. Res.25(6), 1412–1419 (2008).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine27(3), 454–459 (2009).
   PubMed Web of Science ®Google Scholar
• Villemejane J, Mir LM. Physical methods of nucleic acid transfer: general concepts and applications. Br. J. Pharmacol.157(2), 207–219 (2009).
   PubMed Web of Science ®Google Scholar
• Donnelly J, Berry K, Ulmer JB. Technical and regulatory hurdles for DNA vaccines. Int. J. Parasitol.33(5–6), 457–467 (2003).
   PubMed Web of Science ®Google Scholar
• Rai K, Gupta Y, Jain A, Jain SK. Transfersomes: self-optimizing carriers for bioactives. PDA J. Pharm. Sci. Technol.62(5), 362–379 (2008).
   PubMedGoogle Scholar
• Osorio M, Wu Y, Singh S et al. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infect. Immun.77(4), 1475–1482 (2009).
   PubMed Web of Science ®Google Scholar
• Liu D. Listeria -based anti-infective vaccine strategies. Recent Pat. Antiinfect. Drug Discov.1(3), 281–290 (2006).
   PubMedGoogle Scholar
• Schoen C, Loeffler DI, Frentzen A, Pilgrim S, Goebel W, Stritzker J. Listeria monocytogenes as novel carrier system for the development of live vaccines. Int. J. Med. Microbiol.298(1–2), 45–58 (2008).
   PubMed Web of Science ®Google Scholar
• Kaminski RW, Turbyfill KR, Chao C, Ching WM, Oaks EV. Mucosal adjuvanticity of Shigella Invaplex with DNA-based vaccines. Clin. Vaccine Immunol.16(4), 574–586 (2009).
   PubMedGoogle Scholar
• Autenrieth SE, Autenrieth IB. Yersinia enterocolitica : subversion of adaptive immunity and implications for vaccine development. Int. J. Med. Microbiol.298(1–2), 69–77 (2008).
   PubMed Web of Science ®Google Scholar
• Brun P, Zumbo A, Castagliuolo I et al. Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli.Vaccine26(16), 1934–1941 (2008).
   PubMed Web of Science ®Google Scholar
• Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev.60(8), 915–928 (2008).
   PubMed Web of Science ®Google Scholar
• Barouch DH, McKay PF, Sumida SM et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming–viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol.77(16), 8729–8735 (2003).
   PubMed Web of Science ®Google Scholar
• Melkebeek V, Van den Broeck W, Verdonck F, Goddeeris BM, Cox E. Effect of plasmid DNA encoding the porcine granulocyte-macrophage colony-stimulating factor on antigen-presenting cells in pigs. Vet. Immunol. Immunopathol.125(3–4), 354–360 (2008).
   PubMed Web of Science ®Google Scholar
• Laddy DJ, Weiner DB. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int. Rev. Immunol.25(3–4), 99–123 (2006).
   PubMed Web of Science ®Google Scholar
• Perales MA, Yuan J, Powel S et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol. Ther.16(12), 2022–2029 (2008).
   PubMed Web of Science ®Google Scholar
• Xu R, Megati S, Roopchand V et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine26(37), 4819–4829 (2008).
   PubMed Web of Science ®Google Scholar
• Wang LM, Bai YL, Shi CH et al. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin-2 against Mycobacterium tuberculosis in BALB/c mice. APMIS116(12), 1071–1081 (2008).
   PubMed Web of Science ®Google Scholar
• Changhong S, Hai Z, Limei W et al. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis (Edinb.)89(1), 54–61 (2009).
   PubMed Web of Science ®Google Scholar
• Tang M, Wang H, Zhou S, Tian G. Enhancement of the immunogenicity of an infectious bronchitis virus DNA vaccine by a bicistronic plasmid encoding nucleocapsid protein and interleukin-2. J. Virol. Methods149(1), 42–48 (2008).
   PubMed Web of Science ®Google Scholar
• Lin CT, Tsai YC, He L et al. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol. Lett.114(2), 86–93 (2007).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Santra S, Steenbeke TD et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol.161(4), 1875–1882 (1998).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Truitt DM, Letvin NL. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine22(23–24), 3092–3097 (2004).
   PubMed Web of Science ®Google Scholar
• Chong SY, Egan MA, Kutzler MA et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine25(26), 4967–4982 (2007).
   PubMed Web of Science ®Google Scholar
• Wei F, Liu Q, Gao S et al. Enhancement by IL-18 of the protective effect of a Schistosoma japonicum 26kDa GST plasmid DNA vaccine in mice. Vaccine26(33), 4145–4149 (2008).
   PubMed Web of Science ®Google Scholar
• Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4+ T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo.J. Virol.74(23), 11173–11180 (2000).
   PubMed Web of Science ®Google Scholar
• Asif M, Jenkins KA, Hilton LS, Kimpton WG, Bean AG, Lowenthal JW. Cytokines as adjuvants for avian vaccines. Immunol. Cell. Biol.82(6), 638–643 (2004).
   PubMed Web of Science ®Google Scholar
• Sumida SM, McKay PF, Truitt DM et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J. Clin. Invest.114(9), 1334–1342 (2004).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Nottingham LK, Sin JI et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J. Clin. Invest.102(6), 1112–1124 (1998).
   PubMed Web of Science ®Google Scholar
• McKay PF, Barouch DH, Santra S et al. Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur. J. Immunol.34(4), 1011–1020 (2004).
   PubMed Web of Science ®Google Scholar
• Dobano C, Rogers WO, Gowda K, Doolan DL. Targeting antigen to MHC class I and class II antigen presentation pathways for malaria DNA vaccines. Immunol. Lett.111(2), 92–102 (2007).
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J. Immunol.180(1), 309–318 (2008).
   PubMed Web of Science ®Google Scholar
• Drew DR, Boyle JS, Lew AM, Lightowlers MW, Chaplin PJ, Strugnell RA. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep. Vaccine19(31), 4417–4428 (2001).
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature461(7265), 788–792 (2009).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines, vaccination, and vaccinology. J. Infect. Dis.187(9), 1349–1359 (2003).
   PubMed Web of Science ®Google Scholar
• Aravindaram K, Kuo TY, Lan CW et al. Protective immunity against porcine circovirus 2 in mice induced by a gene-based combination vaccination. J. Gene Med.11(4), 288–301 (2009).
   PubMed Web of Science ®Google Scholar
• Steensels M, Bublot M, Van Borm S et al. Prime–boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine27(5), 646–654 (2009).
   PubMed Web of Science ®Google Scholar
• Li P, Cao RB, Zheng QS et al. Enhancement of humoral and cellular immunity in mice against Japanese encephalitis virus using a DNA prime–protein boost vaccine strategy. Vet. J.183(2), 210–216 (2008).
   PubMed Web of Science ®Google Scholar
• Lo CY, Wu Z, Misplon JA et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime–adenovirus boost strategies. Vaccine26(17), 2062–2072 (2008).
   PubMed Web of Science ®Google Scholar
• Chege GK, Shephard EG, Meyers A et al. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J. Gen. Virol.89(Pt 9), 2214–2227 (2008).
   PubMed Web of Science ®Google Scholar
• Patterson LJ, Robert-Guroff M. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin. Biol. Ther.8(9), 1347–1363 (2008).
   PubMed Web of Science ®Google Scholar
• Burgers WA, Shephard E, Monroe JE et al. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res. Hum. Retroviruses24(2), 195–206 (2008).
   PubMed Web of Science ®Google Scholar
• Kent S, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime–boost HIV vaccine. Curr. Opin. Investig. Drugs8(2), 159–167 (2007).
   PubMed Web of Science ®Google Scholar
• Dale CJ, Thomson S, De Rose R et al. Prime–boost strategies in DNA vaccines. Methods Mol. Med.127, 171–197 (2006).
   PubMedGoogle Scholar
• Pan Z, Zhang X, Geng S et al. Priming with a DNA vaccine delivered by attenuated Salmonella typhimurium and boosting with a killed vaccine confers protection of chickens against infection with the H9 subtype of avian influenza virus. Vaccine27(7), 1018–1023 (2009).
   PubMed Web of Science ®Google Scholar
• Heppner DG, Schwenk RJ, Arnot D, Sauerwein RW, Luty AJ. The dog that did not bark: malaria vaccines without antibodies. Trends Parasitol.23(7), 293–296 (2007).
   PubMed Web of Science ®Google Scholar
• Moore AC, Hill AV. Progress in DNA-based heterologous prime–boost immunization strategies for malaria. Immunol. Rev.199, 126–143 (2004).
   PubMed Web of Science ®Google Scholar
• Baillie LW, Rodriguez AL, Moore S et al. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime–boost immunization strategy. Vaccine26(48), 6083–6091 (2008).
   PubMed Web of Science ®Google Scholar
• Xing Z, Charters TJ. Heterologous boost vaccines for bacillus Calmette-Guerin prime immunization against tuberculosis. Expert Rev. Vaccines6(4), 539–546 (2007).
   PubMed Web of Science ®Google Scholar
• Cross AS, Chen WH, Levine MM. A case for immunization against nosocomial infections. J. Leukoc. Biol.83(3), 483–488 (2008).
   PubMed Web of Science ®Google Scholar
• Harthug S, Akselsen PE. Fighting antibiotic resistance. Tidsskr Nor Laegeforen128(20), 2343–2346 (2008).
   PubMedGoogle Scholar
• Yang H, Chen J, Yang G, Zhang XH, Liu R, Xue X. Protection of Japanese flounder (Paralichthys olivaceus ) against Vibrio anguillarum with a DNA vaccine containing the mutated zinc-metalloprotease gene. Vaccine27(15), 2150–2155 (2009).
   PubMed Web of Science ®Google Scholar
• Jiao XD, Zhang M, Hu YH, Sun L. Construction and evaluation of DNA vaccines encoding Edwardsiella tarda antigens. Vaccine27(38), 5195–5202 (2009).
   PubMed Web of Science ®Google Scholar
• Prinz DM, Smithson SL, Kieber-Emmons T, Westerink MA. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology110(2), 242–249 (2003).
   PubMed Web of Science ®Google Scholar
• Park IH, Youn JH, Choi IH, Nahm MH, Kim SJ, Shin JS. Anti-idiotypic antibody as a potential candidate vaccine for Neisseria meningitidis serogroup B. Infect. Immun.73(10), 6399–6406 (2005).
   PubMed Web of Science ®Google Scholar
• Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr. Res.338(23), 2539–2547 (2003).
   PubMed Web of Science ®Google Scholar
• Lesinski GB, Westerink MA. Vaccines against polysaccharide antigens. Curr. Drug Targets Infect. Disord.1(3), 325–334 (2001).
   PubMedGoogle Scholar
• Kieber-Emmons T, Monzavi-Karbassi B, Wang B, Luo P, Weiner DB. Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J. Immunol.165(2), 623–627 (2000).
   PubMed Web of Science ®Google Scholar
• Bona CA. Idiotype vaccines: forgotten but not gone. Nat. Med.4(6), 668–669 (1998).
   PubMed Web of Science ®Google Scholar
• Agarwal K, Agarwal S. Helicobacter pylori vaccine: from past to future. Mayo Clin. Proc.83(2), 169–175 (2008).
   PubMed Web of Science ®Google Scholar
• Kim JM, Kim JS, Kim N et al. Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. J. Microbiol. Biotechnol.18(9), 1584–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Sun B, Li ZS, Tu ZX, Xu GM, Du YQ. Construction of an oral recombinant DNA vaccine from H. pylori neutrophil activating protein and its immunogenicity. World J. Gastroenterol.12(43), 7042–7046 (2006).
   PubMed Web of Science ®Google Scholar
• Xu C, Li ZS, Du YQ et al. Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H. pylori ureB and IL-2. World J. Gastroenterol.13(6), 939–944 (2007).
   PubMed Web of Science ®Google Scholar
• Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter12(2), 89–102 (2007).
   PubMed Web of Science ®Google Scholar
• Todoroki I, Joh T, Watanabe K et al. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori -induced gastritis in mice. Biochem. Biophys. Res. Commun.277(1), 159–163 (2000).
   PubMed Web of Science ®Google Scholar
• Little SF. Anthrax vaccines: a development update. BioDrugs19(4), 233–245 (2005).
   PubMed Web of Science ®Google Scholar
• Manthorpe M, Hobart P, Hermanson G et al. Plasmid vaccines and therapeutics: from design to applications. Adv. Biochem. Eng. Biotechnol.99, 41–92 (2005).
   PubMed Web of Science ®Google Scholar
• Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine17(4), 340–344 (1999).
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Hannaman D, Nolan E et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine26(40), 5216–5222 (2008).
   PubMed Web of Science ®Google Scholar
• Lozes E, Huygen K, Content J et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine15(8), 830–833 (1997).
   PubMed Web of Science ®Google Scholar
• Reed SG, Coler RN, Dalemans W et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl Acad. Sci. USA106(7), 2301–2306 (2009).
   PubMed Web of Science ®Google Scholar
• Mollenkopf HJ, Grode L, Mattow J et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime–Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun.72(11), 6471–6479 (2004).
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine27(25–26), 3267–3270 (2009).
   PubMed Web of Science ®Google Scholar
• Fan X, Gao Q, Fu R. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model. Microbiol. Res.164(4), 374–382 (2007).
   PubMed Web of Science ®Google Scholar
• Cai H, Yu DH, Hu XD, Li SX, Zhu YX. A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge. DNA Cell Biol.25(8), 438–447 (2006).
   PubMed Web of Science ®Google Scholar
• Derrick SC, Repique C, Snoy P, Yang AL, Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis.Infect. Immun.72(3), 1685–1692 (2004).
   PubMed Web of Science ®Google Scholar
• D’Souza S, Rosseels V, Denis O et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect. Immun.70(7), 3681–3688 (2002).
   PubMed Web of Science ®Google Scholar
• Rosada RS, de la Torre LG, Frantz FG et al. Protection against tuberculosis by a single intranasal administration of DNA–hsp65 vaccine complexed with cationic liposomes. BMC Immunol.9, 38 (2008).
   PubMed Web of Science ®Google Scholar
• Orme IM. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine24(1), 2–19 (2006).
   PubMed Web of Science ®Google Scholar
• Walsh GP, Tan EV, dela Cruz EC et al. The Philippine cynomolgus monkey (Macaca fasicularis ) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat. Med.2(4), 430–436 (1996).
   PubMed Web of Science ®Google Scholar
• Okada M. [Novel vaccines against M. tuberculosis.] Kekkaku81(12), 745–751 (2006).
   PubMedGoogle Scholar
• Yager EJ, Dean HJ, Fuller DH. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev. Vaccines8(9), 1205–1220 (2009).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Envisioning future strategies for vaccination against tuberculosis. Nat. Rev. Immunol.6(9), 699–704 (2006).
   PubMed Web of Science ®Google Scholar
• McShane H. Vaccine strategies against tuberculosis. Swiss Med. Wkly139(11–12), 156–160 (2009).
   PubMed Web of Science ®Google Scholar
• Gentschev I, Spreng S, Sieber H et al. Vivotif – a ‘magic shield’ for protection against typhoid fever and delivery of heterologous antigens. Chemotherapy53(3), 177–180 (2007).
   PubMed Web of Science ®Google Scholar
• Sabitha P, Prabha Adhikari MR, Chowdary A et al. Comparison of the immunogenicity and safety of two different brands of Salmonella typhi Vi capsular polysaccharide vaccine. Indian J. Med. Sci.58(4), 141–149 (2004).
   PubMedGoogle Scholar
• Katare YK, Panda AK. Immunogenicity and lower dose requirement of polymer entrapped tetanus toxoid co-administered with alum. Vaccine24(17), 3599–3608 (2006).
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Keitel W, Keyserling H et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine24(33–34), 5950–5959 (2006).
   PubMed Web of Science ®Google Scholar
• Godfroid F, Denoël P, de Grave D, Schuerman L, Poolman J. Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses. Int. J. Med. Microbiol.294(5), 269–276 (2004).
   PubMed Web of Science ®Google Scholar
• Curran MP, Goa KL. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). Drugs63(7), 673–682; discussion 683–684 (2003).
   PubMed Web of Science ®Google Scholar
• Woodard JL, Berman DM. Prevention of meningococcal disease. Fetal Pediatr. Pathol.25(6), 311–319 (2006).
   PubMed Web of Science ®Google Scholar
• Arvas A, Gur E, Bahar H et al.Haemophilus influenzae type b antibodies in vaccinated and non-vaccinated children. Pediatr. Int.50(4), 469–473 (2008).
   PubMed Web of Science ®Google Scholar
• Hare ND, Smith BJ, Ballas ZK. Antibody response to pneumococcal vaccination as a function of preimmunization titer. J. Allergy Clin. Immunol.123(1), 195–200 (2009).
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin. Vaccine Immunol.15(3), 499–505 (2008).
   PubMedGoogle Scholar
• Kunitomo E, Terao Y, Okamoto S, Rikimaru T, Hamada S, Kawabata S. Molecular and biological characterization of histidine triad protein in group A streptococci. Microbes Infect.10(4), 414–423 (2008).
   PubMed Web of Science ®Google Scholar
• Turnes CG, Aleixo JA, Monteiro AV, Dellagostin OA. DNA inoculation with a plasmid vector carrying the faeG adhesin gene of Escherichia coli K88ab induced immune responses in mice and pigs. Vaccine17(15–16), 2089–2095 (1999).
   PubMed Web of Science ®Google Scholar
• Stratford R, Douce G, Zhang-Barber L, Fairweather N, Eskola J, Dougan G. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine19(7–8), 810–815 (2000).
   PubMed Web of Science ®Google Scholar
• Yu YZ, Zhang SM, Sun ZW, Wang S, Yu WY. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine25(52), 8843–8850 (2007).
   PubMed Web of Science ®Google Scholar
• López-Macías C, López-Hernández MA, González CR, Isibasi A, Ortiz-Navarrete V. Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization. Ann. NY Acad. Sci.772, 285–288 (1995).
   PubMed Web of Science ®Google Scholar
• Zhu D, Williams JN, Rice J, Stevenson FK, Heckels JE, Christodoulides M. A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis.Infect. Immun.76(1), 334–338 (2008).
   PubMed Web of Science ®Google Scholar
• Sardiñas G, Yero D, Climent Y, Caballero E, Cobas K, Niebla O. Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential. J. Med. Microbiol.58(Pt 2), 196–208 (2009).
   PubMed Web of Science ®Google Scholar
• Beninati C, Arseni S, Mancuso G et al. Protective immunization against group B meningococci using anti-idiotypic mimics of the capsular polysaccharide. J. Immunol.172(4), 2461–2468 (2004).
   PubMed Web of Science ®Google Scholar
• Fensterle J, Grode L, Hess J, Kaufmann SH. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun. J. Immunol.163(8), 4510–4518 (1999).
   PubMed Web of Science ®Google Scholar
• Barry RA, Archie Bouwer HG, Clark TR, Cornell KA, Hinrichs DJ. Protection of interferon-γ knockout mice against Listeria monocytogenes challenge following intramuscular immunization with DNA vaccines encoding listeriolysin O. Vaccine21(17–18), 2122–2132 (2003).
   PubMed Web of Science ®Google Scholar
• Miyashita M, Joh T, Watanabe K et al. Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori -catalase. Vaccine20(17–18), 2336–2342 (2002).
   PubMed Web of Science ®Google Scholar
• Seepersaud R, Hanniffy SB, Mayne P, Sizer P, Le Page R, Wells JM. Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity. Infect. Immun.73(3), 1671–1683 (2005).
   PubMed Web of Science ®Google Scholar
• Roth DM, Senna JP, Machado DC. Evaluation of the humoral immune response in BALB/c mice immunized with a naked DNA vaccine anti-methicillin-resistant Staphylococcus aureus.Genet. Mol. Res.5(3), 503–512 (2006).
   PubMed Web of Science ®Google Scholar
• Gaudreau MC, Lacasse P, Talbot BG. Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus.Vaccine25(5), 814–824 (2007).
   PubMed Web of Science ®Google Scholar
• Bouzari S, Dashti A, Jafari A, Oloomi M. Immune response against adhesins of enteroaggregative Escherichia coli immunized by three different vaccination strategies (DNA/DNA, protein/protein, and DNA/protein) in mice. Comp. Immunol. Microbiol. Infect. Dis.33(3), 215–225 (2010).
   PubMed Web of Science ®Google Scholar
• Li Z, Wang S, Wu Y, Zhong G, Chen D. Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice. Sci. China C Life Sci.51(11), 973–980 (2008).
   PubMedGoogle Scholar
• Penttilä T, Tammiruusu A, Liljeström P et al. DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model. Vaccine22(25–26), 3386–3394 (2004).
   PubMed Web of Science ®Google Scholar
• Lai WC, Bennett M, Johnston SA, Barry MA, Pakes SP. Protection against Mycoplasma pulmonis infection by genetic vaccination. DNA Cell Biol.14(7), 643–651 (1995).
   PubMed Web of Science ®Google Scholar
• Lai WC, Pakes SP, Ren K, Lu YS, Bennett M. Therapeutic effect of DNA immunization of genetically susceptible mice infected with virulent Mycoplasma pulmonis.J. Immunol.158(6), 2513–2516 (1997).
   PubMed Web of Science ®Google Scholar
• Chessa B, Pittau M, Puricelli M et al. Genetic immunization with the immunodominant antigen P48 of Mycoplasma agalactiae stimulates a mixed adaptive immune response in BALBc mice. Res. Vet. Sci.86(3), 414–420 (2008).
   PubMed Web of Science ®Google Scholar
• Luke CJ, Carner K, Liang X, Barbour AG. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.J. Infect. Dis.175(1), 91–97 (1997).
   PubMed Web of Science ®Google Scholar
• Scheiblhofer S, Weiss R, Dürnberger H et al. A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes Infect.5(11), 939–946 (2003).
   PubMed Web of Science ®Google Scholar
• Singha H, Mallick AI, Jana C et al. Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus.Microbes Infect.10(10–11), 1089–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Hornef MW, Noll A, Schirmbeck R, Reimann J, Autenrieth IB. DNA vaccination using coexpression of cytokine genes with a bacterial gene encoding a 60-kDa heat shock protein. Med. Microbiol. Immunol.189(2), 97–104 (2000).
   PubMed Web of Science ®Google Scholar
• Worgall S, Krause A, Rivara M et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J. Clin. Invest.115(5), 1281–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Saha S, Takeshita F, Matsuda T et al. Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine. J. Immunol.179(2), 1147–1154 (2007).
   PubMed Web of Science ®Google Scholar
• Bentancor LV, Bilen M, Fernández Brando RJ et al. DNA vaccine encoding the enterohemorragic Escherichia coli (EHEC) Shiga-like toxin 2 (Stx2) A2 and B subunits confers protective immunity to Stx challenge in the murine model. Clin. Vaccine Immunol. DOI: 10.1128/CVI.00328-08 (2009) (Epub ahead of print).
   PubMedGoogle Scholar